AIDS treatment drugs can cut infections: study
AIDS drugs designed to treat HIV can also be used to reduce dramatically the risk of infection among heterosexual couples, two studies conducted in Africa showed for the first time yesterday.
The findings add to growing evidence that the type of medicines prescribed since the mid-1990s to treat people who are already sick may also hold the key to slowing or even halting the spread of the sexually transmitted disease.
The research involving couples in Kenya, Uganda and Botswana found that giving daily AIDS drugs reduced infection rates by an average of at least 62 percent when compared with placebo.
"Effective new HIV prevention tools are urgently needed and these studies could have enormous impact in preventing heterosexual transmission," Margaret Chan, director-general of the World Health Organization, said in a statement.
In an indication of the importance of the latest evidence, Chan said the United Nations health agency would now work with countries to use the new findings to implement better protection strategies.
The larger of the two studies examined 4,758 couples in Kenya and Uganda in which one partner was HIV-positive and one was negative. Those negative partners taking Gilead Sciences Inc's tenofovir, or Viread, had on average 62 percent fewer infections.
For couples on Truvada - another Gilead drug combining tenofovir and emtricitabine - the infection risk was cut by an estimated 73 percent in the clinical trial, which was led by researchers at the University of Washington.
The study was funded by the Bill & Melinda Gates Foundation, whose director of HIV and Tuberculosis, Stefano Bertozzi, said it marked "a significant milestone in the quest to develop new HIV prevention measures."
The second study, involving just over 1,200 sexually active men and women in Botswana, found those on daily Truvada reduced their risk of HIV infection by 62.6 percent.
The idea of such "pre-exposure prophylaxis," known as PrEP, has gained traction in the past year, following results of other research showing a fall in infection rates among gay men taking AIDS drugs. However, PrEP took a knock earlier this year when another study failed to demonstrate a protective effect in high-risk women.
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔$粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.